News Articles

March 20, 2020 – Care of Individuals with Cancer During COVID-19

ASCO invited its members to submit questions about issues and challenges they see emerging while caring for individuals with cancer in the context of the coronavirus pandemic. Currently, limited clinical cancer-specific data are available and information is evolving. The following information is based on evidence gathered through a PubMed searches of the medical literature, a search of relevant websites with information on infectious diseases (CDC, WHO, IDSA, etc.), and input provided by clinical oncologists and infectious disease experts. ASCO will update this information as new questions emerge and evidence develops.

View Full Article

January 30, 2020 – Family History of Gastric Cancer and Helicobacter Pylori Treatment

Helicobacter pylori infection and a family history of gastric cancer are the main risk factors for gastric cancer. Whether treatment to eradicate H. pylori can reduce the risk of gastric cancer in persons with a family history of gastric cancer in first-degree relatives is unknown.

View Full Article

January 15, 2020 – Early-Onset Gastric Cancer, Distinct From Traditional Disease, On The Rise In US

Incidence of early-onset gastric cancer that is clinically and genetically distinct from late-onset disease has increased steadily in the United States, an “alarming phenomenon” that warrants further research, according to a study published in Surgery.

“There is an increasing trend of young patients diagnosed with gastric cancer, but without any of the traditional risk factors of gastric cancer. We wanted to find out why we are seeing this and what we might be able to do about it,” Travis E. Grotz, MD, surgical oncologist at Mayo Clinic in Rochester, Minnesota, told Healio.

View Full Article

January 6, 2020 – Leap, BeiGene to Develop Immunotherapy for Gastric Cancer

US based Leap Therapeutics, Inc. a biotechnology company developing targeted immuno-oncology therapeutics, and China headquartered BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, on 3 Jan 2020 announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.

View Full Article

November 16, 2019 – FDA Approves Talicia To Treat Superbug Linked To Stomach Cancer

Health officials are increasingly concerned about the rise of antibiotic-resistant infections, also known as ‘superbugs’. However, this month an Israel-based pharmaceutical company showed that we may be able to combat this threat.

View Full Article

November 12, 2019 – FDA Grants Breakthrough Status to AI-Based Gastric Cancer Diagnostic

The FDA granted breakthrough device designation to AI Medical Service’s technology for diagnosing gastric cancer, the company said Monday. The technology uses artificial intelligence to analyze endoscopy images for signs of gastric cancer, a hard-to-diagnose disease associated with a high rate of false negatives. AI Medical Service, which raised $42.9 million last month, is working to bring the technology to the U.S. and its home market of Japan.

View Full Article

November 1, 2019 – Taiho Oncology Joins Efforts To Improve Awareness Of Gastric Cancer With Support Of Leading Advocacy Groups

Recognizing a need for greater awareness and education around gastric cancer, Taiho Oncology, Inc., today announced its support of four leading gastric cancer advocacy organizations in observance of National Gastric Cancer Awareness Month. The company is sponsoring patient and caregiver programs, education and research throughout 2019 on behalf of Debbie’s Dream Foundation, the Gastric Cancer Foundation, Hope for Stomach Cancer and No Stomach For Cancer®.

View Full Article

October 14, 2019 – ANALYSIS OF PATIENTS WITH PRIOR GASTRECTOMY TREATED WITH LONSURF® (TRIFLURIDINE AND TIPIRACIL) PUBLISHED IN JAMA ONCOLOGY

Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the October 10, 2019 issue of JAMA Oncology.

View Full Article

July 3, 2019 – Gastric Cancer Rates Higher Among Patients Treated For H. Pylori

Patients who receive antibiotic treatment for Helicobacter pylori infection experience gastric cancer at rates higher than the general population and several risk factors can increase that risk even further, according to data presented at Digestive Disease Week.

View Full Article

July 4, 2019 – Study Uncovers Origin of Cell Layer that Hides Stomach Cancer

A group of researchers from Hiroshima recently discovered the origin of a normal-looking stomach lining that covers sites of gastric cancer and makes it difficult to spot after the eradication of an H. pylori infection. H. pylori infection is a major cause of stomach cancer and causes inflammation by releasing substances that can destroy cells that line the stomach. This destruction and regeneration of tissue can lead to stomach cancer. This study found that even after treatment of the infection, H. pylori leaves behind layers of cells that seem normal but actually originate from stomach cancer tissue. Thus, clinicians should be aware of these layers as to not miss potential stomach cancer sites when treating patients who have been treated for H. pylori infection.

View Full Article